Navigation Links
Materia Licenses Metathesis Catalyst Platform to Eisai

PASADENA, Calif.--(BUSINESS WIRE)--Jun 20, 2007 - Materia, Inc., a catalyst technology company, announced today the licensing of its metathesis platform to Eisai Co., Ltd., a leading Japanese pharmaceutical company, for use in drug discovery and development. The non-exclusive license agreement provides rights to discover, develop, and patent pharmaceutical compounds and related processes using the Company's catalysts and associated intellectual property.

Metathesis catalysts enable the formation and manipulation of carbon-carbon bonds in the synthesis of entirely new pharmaceutical products with superior properties as well as in the development of new, more efficient and low cost production processes for existing products. Materia's catalysts include those from Professor Robert Grubbs at Caltech who won the Nobel Prize for the technology in 2005.

"We are pleased that Eisai accepts the value of Materia's technology in drug discovery and process chemistry and look forward to its exciting progress," stated Dr. Michael Giardello, Materia's Chief Executive Officer. "We believe that this agreement further validates metathesis' broad potential for the pharmaceutical industry and Materia's unique intellectual property and position as the partner of choice."

About Materia

Materia was founded in 1998 to commercialize olefin metathesis catalyst technology. This market-enabling, Nobel Prize winning, green chemical technology enables chemical compounds to be synthesized with greater efficiency, under less stringent reaction conditions, and with reduced byproducts and hazardous waste. As stated by the Royal Swedish Academy of Sciences when awarding the 2005 Nobel Prize, "metathesis is an example of how important basic science has been applied for the benefit of man, society, and the environment." For more information, visit: www.materia-inc.com.

Contact

Materia, Inc.
John Kibler, 626- 584-8400


'"/>




Related medicine technology :

1. Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Companys Investigational Drug to Treat Cocaine and Methamphetamine Addiction
2. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
3. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
4. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
5. Abraxis BioScience Presents Pre-Clinical Findings That Support Role of SPARC Expression in Cancer and the Role of the Nanoparticle Albumin Bound (nab) Technology Platform in Targeting the Pathway
6. AVEO Pharmaceuticals Novel Oncology Research Platform and Clinical Pipeline to Be Featured at AACR
7. Clinical Data on Eisais Oncology Pipeline to be Presented at ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ROCKVILLE, Md. , Sept. 22, 2017  As ... by Republican Senators Bill Cassidy (R-LA) and ... Kalorama Information notes that the medical device industry is ... the medical device tax, the 2.3% excise tax on ... Act.  But they also want covered patients, increased visits ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
(Date:9/18/2017)... , Pa. and KALAMAZOO, Mich. , ... Allentown, Penn. , and OptiMed Specialty Pharmacy of ... business partnership to offer a strategic hub service that ... Healthcare,s highly sought-after personal spirometer, Spiro PD 2.0, and ... A spirometer is a medical device used to ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... leader in post-acute health care, have expanded their existing home health joint venture ... , AccentCare has been operating a joint venture home health company with Asante, ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader ... a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were ... 11, 2017. , The annual award competition recognizes editorial and design excellence across a ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... one of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. ... awards program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief Medical ... to physician colleagues, skilled nursing facility medical directors and other clinicians at various ... Wound Care." , "At many of these conferences we get to educate other ...
Breaking Medicine News(10 mins):